Author Archives: admin


Direct reprogramming of human fibroblasts into insulin-producing … – Nature.com

Exogenous expression of the transcription factors Pdx1, Neurog3, and MafA in human fibroblasts

We first sought to examine whether the transcription factors Neurog3, Pdx1, and MafA could induce expression of the INSULIN (INS) gene in human fibroblasts as readout of the capacity of these cells to be transformed toward a -cell fate. To deliver these factors we employed a polycistronic adenoviral vector carrying the three transgenes (Ad-NPM hereafter), which had been previously used to promote -cell reprogramming from pancreatic acinar cells19. After optimization of adenoviral transduction in fibroblasts (see Methods), abundant (>80%) cells positive for Cherry, which is also encoded by Ad-NPM, were easily observable three and seven days after viral infection (Fig.1a). Likewise, high levels of transcripts encoding the NPM factors were expressed at both time points (Fig.1b). Three days after addition of Ad-NPM we detected marginal levels of INS mRNA that were increased >10-fold by day 7 (Fig.1c). As cell culture formulations can have a major impact on gene expression events and cellular reprogramming, we tested different conditions after Ad-NPM infection. We observed that moving to RPMI-1640 and, to a lesser extent, CMRL-1066 medium and lowering the fetal calf serum concentration to 6% dramatically boosted INS gene activation, reaching values that were 0.12% those of human islets (Fig.1d and Supplementary Figure1). Under the same culture conditions, only a very marginal induction of the INS gene occurred when the N+P+M factors were delivered simultaneously via distinct adenoviruses to human fibroblasts (Supplementary Fig.2). In addition to INS, we discovered that the NPM factors also activated the hormone genes GLUCAGON (GCG) and SOMATOSTATIN (SST), albeit at lower levels than INS as indicated by decreased relative expression values (compared to the housekeeping gene TBP) (Fig.1e). The NPM factors also induced expression of genes encoding islet differentiation transcription factors including NEUROD1, INSM1, PAX4, NKX2-2, and ARX (Fig.1f).

Human fibroblasts (HFF1) were infected with a polycistronic recombinant adenovirus encoding the transcription factors Neurog3, Pdx1, MafA, and the reporter protein Cherry (Ad-NPM). Untreated parental fibroblasts were used as controls (indicated as C in graphs). a Bright field images and Cherry immunofluorescence of control fibroblasts and fibroblasts infected with Ad-NPM at day 3 and 7 post-infection. Scale bar, 100 m. b qPCR of transgenes at day 3 (n=11) and 7 (n=6) after infection with Ad-NPM. c qPCR of human INS at day 3 (n=7) and 7 (n=13) after infection with Ad-NPM. d qPCR of human INS in fibroblasts maintained in the indicated culture media (DM=DMEM; CM=CMRL; RP=RPMI) during 7 days after infection with Ad-NPM or with an adenovirus expressing B-galactosidase (B-gal) (n=310). In yellow, INS mRNA levels in isolated human islets (n=10). e, f qPCR of islet hormone genes (GCG, SST) and islet differentiation transcription factors (NEUROD1, INSM1, PAX4, NKX2-2, ARX) at day 7 post-NPM (n=815). g qPCR of the indicated fibroblast markers at day 3 (n=511) and day 7 post-NPM (n=56). In bf, expression levels are expressed relative to TBP. In g, expression is expressed relative to control fibroblasts, given the value of 1 (dotted line). Data are presented as the meanSEM for the number of samples indicated in parentheses. *P<0.05; **P<0.01; ***P<0.001, between indicated conditions using unpaired t-test (bf), or relative to control fibroblasts using one sample t-test (g).

To further establish if the NPM factors promoted cell fate conversion and not simply activated their target genes in fibroblasts, we surveyed expression of genes associated with the fibroblastic signature, including several factors involved in maintenance of the fibroblastic transcriptional network such as TWIST2, PRRX1, and LHX920. We found that these genes were downregulated as early as three days after NPM introduction. Other fibroblast markers exhibited a more delayed response but, by day 7 post-NPM, all tested genes exhibited significant down-regulation (Fig.1g). Together, these experiments validate that islet cell fate can be induced in human fibroblasts using a defined set of transcription factors.

The observed induction of the islet hormone genes GCG and SST implied that the NPM factors might not specifically endorse -cell fate in fibroblasts. Furthermore, we found that these factors did not induce NKX6-1, which encodes a -cell specific factor required for the formation of pancreatic cells during development21 and key for optimal maturation of stem cell cells in vivo22,23 (Fig.2a). These findings indicated that the NPM factors sub-optimally promoted a -cell state in human fibroblasts. In order to enhance -cell fate over other islet cell identities, we opted to add new transcription factors to the reprogramming cocktail.

Human fibroblasts (HFF1) were infected with Ad-NPM alone or sequentially with Ad-NPM and adenoviruses encoding the transcription factors Pax4 and Nkx2-2. Ad-Pax4 and Ad-Nkx2-2 were added three days after NPM in the two-virus conditions. In the three-virus condition, Pax4 was added three days and Nkx2-2 and six days after NPM (condition called 5TF). All cells were collected ten days after infection with Ad-NPM. a qPCR of the indicated transgenes and endogenous genes. Expression levels are calculated relative to TBP. Values represent the meanSEM (n=412). b Representative immunofluorescence images showing insulin staining (in red) using two different antibodies, one against C-PEP, in untreated fibroblasts and in fibroblasts infected with Ad-NPM alone or with 5TF. Nuclei were stained with Hoechst (in blue). Scale bar, 25 m. *P<0.05; ****P<0.0001 relative to NPM in (b) using one-way ANOVA and Tukeys multiple comparison test.

Pax4 is activated downstream of Neurog3 during development24 and has been shown to favor - over -cell specification25,26, and to contribute to maintenance of the expression of Nkx6.1 in differentiating cells27. Despite that the NPM factors induced endogenous PAX4 mRNA, the expression levels attained might not be sufficient to endorse - over -cell fate. Hence, we treated fibroblasts with an adenovirus encoding Pax4 three days after NPM (Fig.2a). This resulted in the significant enhancement of INS expression as compared to NPM alone but, unexpectedly, GCG expression was also increased (Fig.2a), indicating that ectopic Pax4 improved islet hormone gene expression without apparent impact on - versus -cell fate conversion in human fibroblasts.

As the NKX6-1 gene remained silent in response to NPM+Pax4 (Fig.2a), we tried directly adding Nkx6-1 to the NPM reprogramming cocktail. However, exogenous Nkx6-1 resulted in considerable cell death irrespective of level of expression or timing of introduction. As an alternate approach, we added exogenous Nkx2-2, which also regulates early -cell differentiation and is an upstream activator of Nkx6-1 during mouse islet development21. Treatment with an adenovirus encoding Nkx2-2 three days after NPM led to endogenous activation of NKX6-1 expression with no compromise of fibroblast viability (Fig.2a). Nkx2-2 also induced PAX6, a pan-endocrine gene required to achieve high levels of islet hormone gene expression during mouse pancreas development28,29. Remarkably, ectopic Nkx2-2 reduced NPM-induced GCG gene activation without affecting INS gene expression (Fig.2a).

During development, Pax4 and Nkx2-2 are found in -cell precursors at around the same time, and their parallel activities are thought to enable the -cell differentiation program27. Hence, we tested the effects of including both transcription factors in the reprogramming cocktail. To ensure optimal expression of each transcription factor, we treated cells with Ad-Pax4 and Ad-Nkx2.2 sequentially, at day 3 and day 6 post-NPM, respectively. Following this protocol, the blockade of GCG gene activation and the induction of the NKX6.1 and PAX6 genes seen with NPM+Nkx2.2, and the higher INS expression elicited by NPM+Pax4 relative to NPM alone were all maintained (Fig.2a). Neither Pax4 nor Nkx2-2, added alone or together, had any impact on the minimal INS gene induction shown when the N+P+M factors were delivered via separate adenoviruses to human fibroblasts (Supplementary Fig.2).

Consistent with the gene expression data, staining for insulin protein was more robust in cells reprogrammed with NPM+Pax4+Nkx2.2 than in cells reprogrammed with NPM as assessed using two different antibodies, one against human insulin and another against human C-PEP to exclude possible insulin uptake from the media (Fig.2b). We quantified the immunofluorescence images and found that 67.96.2% of cells in the culture were INS+at day 10.

From here on, we used the sequential introduction of the five transcription factors (5TF protocol, Fig.3a) to generate insulin-producing cells from human fibroblasts (reprogrammed cells will be referred as 5TF cells). At day 10, 5TF cells displayed an epithelial morphology (Fig.3b) and hadnt grown as much as untreated fibroblasts (day 10; 5TF: 441033103 cells/well; control: 23810318103 cells/well, n=18). This decreased cell number was likely due to diminished proliferation, which was evident as soon as one day following Ad-NPM infection (Fig.3c). The capacity of cells to reduce the MTT compound, in contrast, was comparable to that of fibroblasts, indicating that viability was not compromised (Fig.3d).

a Scheme of the reprogramming protocol 5TF (NPM+Pax4+Nkx2.2) showing the sequence of addition of adenoviruses encoding the indicated transcription factor/s. Duration of incubation with each adenovirus is represented with a line. Cells were studied at days 10-11 after initial addition of Ad-NPM. b Representative bright field image of parental fibroblasts and 5TF reprogrammed fibroblasts at day 10. Scale bar, 75 m. c Cell proliferation measured by BrdU incorporation and d cell viability measured by MTT assay for n=3 independent reprogramming experiments. Bars represent values relative to control fibroblasts (given the value of 1, represented by a dotted line). Note that day 4 values are before Pax4 introduction. e, f qPCR of islet/-cell transcription factor and -cell function genes in untreated control fibroblasts (C, n=522), in fibroblasts infected with Ad-NPM alone (n=322) or with 5TF (n=522). Expression levels were calculated relative to TBP. qPCR of the indicated endogenous genes (g) and transgenes (h) at day 21 after initiation of reprogramming (n=913, from 7 reprogramming experiments). Transcript levels are expressed relative to levels in cells at day 10 of the reprogramming protocol (given the value of 1, shown with a dotted line). Data are meanSEM for the number of n indicated in parentheses. *P<0.05, **P<0.01, ***P<0.001 compared to control fibroblasts (c, d), or between indicated bars using unpaired t-test (e, f), or compared to day 10 5TF cells (g, h) using one-sample t-test.

Next we studied expression of selected differentiation transcription factor genes at days 10-11 of the protocol. All genes tested, except PAX4, were more expressed in 5TF relative to NPM (NEUROD1, INSM1, HNF1B, MAFB, PDX1, NEUROG3, NKX2.2) (Fig.3e). Likewise, several genes (PCSK1, KCNJ11, GLP1R, NCAM1) that are linked to -cell function were increased in 5TF cells as compared to NPM cells (Fig.3f). Remarkably, some genes were induced de novo by 5TF (ABCC8, GIPR) (Fig.3f). In line with a loss of GCG activation, the pro-convertase gene PCSK2, which is expressed at higher levels in than in cells30, was reduced by 5TF as compared to NPM (Fig.3f). These results support that sequential introduction of Pax4 and Nkx2-2 after NPM endorses the -cell differentiation program in human fibroblasts. -cell gene activation was sustained for at least twenty-one days after initiation of the protocol despite reduced expression of the reprogramming factor transgenes (Fig.3g, h). Furthermore, expression of several of the tested genes increased with time in culture including NKX6-1, PCSK1, KCNJ11, ABCC8 and CHGB among others (Fig.3g), suggestive of permanent cell lineage conversion.

Glucose-induced insulin secretion by cells is mediated by cellular glucose metabolism, closure of ATP-dependent potassium channels, membrane depolarization and opening of voltage-dependent calcium channels, resulting in an increase in cytosolic Ca2+ that triggers insulin exocytosis. We investigated whether 5TF cells increased intracellular Ca2+ in response to glucose and membrane depolarization elicited by high potassium. We found that 65% of the cells exhibited a response to glucose, high potassium, or both, whilst 35% of cells were unresponsive to either stimulus (Fig.4a and Supplementary Video1). Parental fibroblasts not engineered for 5TF expression were unresponsive to these stimuli (Fig.4b and Supplementary Video2). Among responsive cells, approximately half responded to both glucose and high potassium and half responded only to potassium (Fig.4a). We observed heterogeneity in the amplitude and kinetics of responses among individual cells (Fig.4c). Next, we performed static incubation assays to study GSIS and found that 5TF cells released similar amounts of human insulin at low (2mM) and high (20mM) glucose concentrations (Fig.4d). Thus, even though 5TF cells increased their intracellular calcium in response to glucose and membrane depolarization, they secreted insulin in a constitutive manner.

5TF cells were loaded with the calcium indicator Fluo-4-AM at day 10 of the reprogramming protocol. Single-cell imaging to detect cytosolic calcium was performed in the following sequence: low glucose (2mM, G2), high glucose (20mM, G20) and membrane depolarization with KCl (30mM). a Quantification of the frequency of cells (n=200, from six independent reprogramming experiments) that responded to glucose, membrane depolarization elicited by high potassium or both. Representative measurements of dynamic Fluo-4 fluorescence for (b) six fibroblasts and (c) four 5TF cells. d In vitro insulin secretion by 5TF cells. ELISA determination of secreted human insulin by control fibroblasts (n=413) and 5TF cells (n=16) under non-stimulatory conditions (glucose 2mM) and under stimulatory conditions (glucose 20mM). Data are meanSEM and correspond to six independent reprogramming experiments, 24 biological replicates per experiment.

The differentiation and functionality of many cell types vary dramatically between three-dimensional (3D) and two-dimensional (2D) monolayer cultures, the former being closer to the natural 3D microenvironment of cells in a living organism. Thus, we generated spheroids of 5TF cells (1200-1800 cells/spheroid; average diameter of 12827m) one day after the introduction of Nkx2-2 and maintained them in culture for three additional days (Fig.5a). At the time of collection, insulin-positive staining was easily identified but glucagon and somatostatin staining was undetectable (Fig.5b and Supplementary Fig.3). While INS transcript levels were nearly 2-fold higher in 5TF cell spheroids compared to 5TF cells kept in monolayer, other -cell marker genes, such as the prohormone convertase PCSK1 and the ATP-sensitive potassium channel subunits KCNJ11 and ABCC8, showed a higher response (4 to 5-fold) to 3D culture (Fig.5c). Thus, cell aggregation during the last stage of reprogramming (note that total length of the protocol was not changed) conferred improved activation of genes associated to -cell function. Despite increased gene activation, -cell gene expression in 5TF cell spheroids remained lower than in human islets, with differences ranging widely among examined genes (Fig.5c).

a Schematic representation of the modified 5TF protocol (5TF-3D): cells were moved from 2D to 3D culture during the last three days (days 710) of the protocol. Representative bright field image of 5TF cell spheroids. Scale bar, 100 m. b Representative immunofluorescence image showing insulin staining in red and nuclei in blue (marked with Hoechst) of a 5TF cell spheroid at the end of the reprogramming protocol. Scale bar is 50 m. c qPCR of the indicated genes in 5TF cell spheroids. Transcript levels are expressed as fold relative to levels in 5TF cells maintained in 2D culture throughout the 10-day protocol (given the value of 1, dotted line). Data are meanSEM for n=412. *P<0.05, **P<0.01, ***P<0.001 relative to 2D culture using one-sample t-test. Fold-change differences in expression levels between human islets and 3D-5TF reprogrammed cells are shown in the upper yellow box. d Heat map of differentially expressed genes between parental fibroblasts (C) and 5TF cell spheroids (n=3 reprogramming experiments). e GSEA plots on indicated gene sets and pathways. f Dot plots showing the enrichment analysis on Gene Ontology (GO) and KEGG categories of differentially expressed genes (gained in red, lost in blue) between fibroblasts (C) and 5TF cells. The X-axis represents the adjusted p value, the size of the dot represents the number of enriched genes (count) and the color intensity of the dots represents the percentage of hits in each category. g GSEA plot on -cell disallowed genes. h Relative expression levels of -cell disallowed genes repressed in 5TF cell spheroids as compared to fibroblasts (given the value of 1) based on RNA-seq data normalized expression values. Data are meanSEM (n=3). Insets show mRNA expression of the indicated genes in untreated control fibroblasts (n=5), 5TF cell spheroids (n=6) and human islets (n=5) as assessed by qPCR. Expression levels were calculated relative to TBP. Data are meanSEM. *P<0.05, **P<0.01 relative to control fibroblasts using unpaired t-test.

To obtain a more comprehensive understanding of thecell identity switch induced by the 5TF-3D reprogramming protocol, we performed RNA-sequencing of 5TF cell spheroids and parental fibroblasts. A total of 2806 genes (1186 upregulated, 1620 downregulated) were differentially expressed between both cell populations (adjusted p-value <0.05 and fold-change (FC)>2) (Fig.5d and Supplementary Data1). Gene set enrichment analysis (GSEA) showed that pancreas/-cell and peptide hormone metabolism gene sets were enriched in 5TF cells (Fig.5e). Biological functions associated with gained genes included epithelium development, synaptic signaling, ion transport, calcium sensing and secretion (Fig.5f). Among the upregulated genes related to stimulus-secretion coupling, there were synaptotagmins (SYT1,2,3,6,13,17), syntaxins (SYN2 SYN3), calcium sensors (SCG2) and SNARE protein complexes (VAMP1). Correlating with our previous results, cell cycle and mitotic function genes were enriched among repressed genes (Fig.5e, f). Additionally, GSEA demonstrated that 5TF cells had a lower expression of the gene set associated with the epithelial-mesenchymal transition (Fig.5e). In agreement, functions including cytoskeleton organization and cellular migration were overrepresented among lost genes (Fig.5f). Interestingly, GSEA also revealed that the -cell disallowed gene set, which includes genes that are selectively suppressed in cells and believed to be detrimental for cell function31,32,33, was reduced in 5TF cells (Fig.5g). A total of 23 previously recognized -cell disallowed were significantly downregulated in 5TF cells (Fig.5h). By using qPCR, we confirmed the repression of three of these genes -OAT, LDHA, and SMAD3- which are regarded as part of the core disallowed unit33. Of note, the levels of these genes in 5TF cells matched those of human islets (Fig.5h). Collectively, these results show that 5TF-3D reprogramming promotes a change in the fibroblast transcriptome, including selective gene activation along with specific gene repression events, enabling a change in cell identity from fibroblast towards a -cell fate.

Consistent with gene activation events identified in prior gene expression analyses, immunofluorescence staining showed the presence of the mature -cell markers PCSK1, NCAM1, and KCNJ11 (Kir6.2) in many insulin-positive 5TF cells. PTPRN (IA2) was also expressed albeit more sporadically in insulin-positive 5TF cells (Fig.6a). Using conventional electron microscopy, we looked for the existence of secretory granules and discovered that most cells contained multiple spherical electron-dense prototypical secretory vesicles (Fig.6b). These vesicles showed a high degree of morphological heterogeneity, presumably as consequence of their degree of maturation and/or loading. Although they did not have the appearance of typical insulin-containing granules from primary cells, which are characterized by a clear halo surrounding a dark polygonal dense core34, some of the vesicles exhibited a gray or less electron dense halo and looked like the granules described in immature insulin-positive cells generated in early stem cell differentiation protocols35,36.

a Representative confocal images of 5TF cell spheroids immunostained with the indicated antibodies. Scale bar, 10 m. b Conventional transmission electron microscopy showing a representative image of a 5TF cell spheroid. Prototypical electron dense secretory vesicles (asterisks) are observed dispersed in the cytoplasm. Well-preserved mitochondria (mit), endoplasmic reticulum (ER), Golgi membranes (G) and lipid droplets (LD) are also observed. Inset shows a detail of a secretory vesicle with an average diameter of 450nm. N, nucleus. Scale bars are 200nm (inset) and 500nm. c In vitro glucose-induced insulin secretion by 5TF cell spheroids (n=14, from 8 reprogramming experiments). Secretion by control spheroids composed of parental fibroblasts (n=5) is also shown. d Glucose stimulation Index (ratio between insulin secreted at 20mM glucose vs. 2mM glucose) of 5TF cells maintained in 2D or in 3D (spheroid) cultures (n=1618, from 8 to 10 reprogramming experiments). e Glucose dose curve of insulin secretion by 5TF cell spheroids (n=412, 5 reprogramming experiments). Data are presented as the meanSEM for the number of n indicated in parentheses. *P<0.05; ***P<0.001 between the indicated conditions using unpaired t-test (c), one sample t-test (d) or one-way ANOVA (e).

We next performed static incubation GSIS assays. 5TF cell spheroids exhibited significant insulin secretory response to glucose (fold 20mM/2mM: 2.020.18) as compared to 2D cultures (fold 20mM/2mM: 1.080.15) (Fig.6c, d). To establish the glucose threshold for stimulation of insulin secretion, 5TF cell spheroids were subjected to either 2,5,11 or 20mM glucose. Between 2mM and 11mM/20mM glucose, 5TF spheroids showed a 2.3-fold increase in insulin production on average (Fig.6e). In contrast, although there was some variability, they did not show a statistically significant increase in insulin secretion between 2mM and 5mM glucose (Fig.6e). These observations indicate that 5TF cell spheroids are stimulated at higher glucose threshold; it is interesting to note that human islets have a glucose threshold at 3mM and a maximal response at 15mM37.

The 5TF-3D protocol was repeated on an additional HFF line and produced results that were comparable (Supplementary Fig.4) proving the reproducibility of the reprogramming protocol.

Finally, we studied the stability of reprogramming in vivo. With this aim, we transplanted 300 5TF cell spheroids (10001200 cells/spheroid) into the anterior chamber of the eye (ACE) of non-diabetic immune-deficient NOD scid gamma (NSG) mice (Fig.7a). The ACE allows fast engraftment38 and in vivo imaging39. Ten days following transplantation, we used two-photon microscopy to evaluate in vivo graft re-vascularization and confirmed the presence of functioning vessels in the grafts (Fig.7b). Additionally, by observing the long-term tracer CFDAs fluorescence, we confirmed that the transplanted cells were alive (Fig.7b). To assess the maintenance of insulin expression in vivo, we harvested the eye grafts at day 10 for RNA extraction and immunostaining. Human INS mRNA was readily detectable and levels, calculated relative to human TBP, were comparable to those in 5TF cell clusters prior to transplantation (Fig.7c). In agreement, abundant HLA+(human cell marker) cells that stained for insulin were detected in the eye grafts by immunofluorescence staining (43.52.8% INS+HLA+/totalHLA+, n=5) (Fig.7d, e and Supplementary Fig.5). We observed positive staining for the reprogramming transcription factors in 2030% of the INS+cells (Supplementary Figure6). Although we were unable to discriminate between the two, high transgene expression found by qPCR analysis in eye grafts (Supplementary Fig.6) indicated that the staining represented virally encoded exogenous protein rather than endogenous protein. Since adenoviral vectors do not normally integrate into the host DNA, we speculate that the cessation of cell division induced by reprogramming may explain persistent transgene expression in 5TF cells. In fact, similar findings were reported in reprogrammed human duct-derived insulin-producing cells9. We were able to identify INS+cells in 4 (of 5) grafts harvested one month after transplantation even though their number was reduced relative to day 10 grafts (Supplementary Fig.7). The proportion of INS+HLA+ cells in 30-day grafts was more heterogeneous than in 10-day grafts, and in 3 (of 5) grafts, it was comparable or even higher than that of 10-day grafts, demonstrating the maintenance of reprogramming (Supplementary Fig.7).

a Schematic illustration and image showing 5TF cell spheroids transplanted into the anterior chamber of the eye (ACE) of a normoglycemic NSG mouse. b Vascularization of 5TF cell grafts ten days following transplantation into the ACE. Representative in vivo image depicting functional vessels (RITC-dextran, red) and viable 5TF cells (CFDA, green). Scale bar, 100 m. c qPCR of INS and TBP transcripts in eyes of non-transplanted mice (nt, n=3) and mice transplanted with either control fibroblast spheroids (C, n=3) or 5TF cell spheroids (n=5) collected ten days post-transplantation. INS gene expression in 5TF cell spheroids prior to transplantation is depicted in the blue bar (n=6). INS gene expression is calculated relative to TBP. Expression of TBP relative to mouse Tbp is shown to prove the presence of human cells in eyes receiving control and 5TF spheroids. Data are presented as meanSEM. d Representative immunofluorescence images showing HLA staining in red and insulin staining in green in 5TF cell grafts ten days post-transplantation. Scale bar, 25 m. e Percentage of cells doubly positive for insulin and HLA (relative to total HLA+cells) in 5TF cell grafts at day 10 following transplantation. Each dot corresponds to one eye graft (n=5). f ELISA determination of human insulin in the aqueous humor in un-transplanted mice (n=7), in mice transplanted with either 300 fibroblast spheroids (n=14) or 300 5TF cell spheroids (n=17) at day 10 post-transplantation and in mice transplanted with 150200 human islets (n=4) at day 1215 post-transplantation. Data are presented as meanSEM for the number of n indicated in parentheses. ***P<0.001; ***P<0.0001 between indicated samples using unpaired t-test.

To study if 5TF cells secreted insulin in vivo, we first measured the presence of human insulin by ELISA in the aqueous humor of the transplanted eyes. Human insulin was readily detectable in eyes carrying 5TF cell grafts (17 of 17, ranging from 76 to 1103 pmol/L) whilst no insulin was detected in eyes transplanted with parental fibroblast clusters or in non-transplanted mice (Fig.7f). For comparison, eyes containing 300 5TF spheroids showed on average approximately 20-fold lower levels of human insulin than eyes containing 150200 human islets (Fig.7f). Due to space limitations in the ACE, we transplanted a larger number of spheroids (35005000) into the omentum of normoglycemic NSG mice in order to detect circulating human insulin in host animals. We measured low amounts of human insulin in the plasma of most transplanted mice, and these levels increased in 6 (of 10) mice after receiving an intraperitoneal glucose injection on day 30 post-transplantation (3.60.9 vs 13.93.7pmol/L, p=0.014) (Supplementary Fig.8). Transplants were repeated in other locations yielding similar results (Supplementary Table2). As observed in the ACE grafts, a low number of INS+cells were identified in omentum grafts harvested at 30 days post-transplantation (Supplementary Fig.8). These findings show that, despite restricted survival, reprogramming is maintained and 5TF cells maintain the capacity to release insulin in an in vivo setting.

View original post here:
Direct reprogramming of human fibroblasts into insulin-producing ... - Nature.com

Gene therapy: Everything you need to know about the DNA … – Livescience.com

Gene therapy has been headline news in recent years, in part due to the rapid development of biotechnology that enables doctors to administer such treatments. Broadly, gene therapies are techniques used to treat or prevent disease by tweaking the content or expression of cells' DNA, often by replacing faulty genes with functional ones.

The term "gene therapy" sometimes appears alongside misinformation about mRNA vaccines, which include the Pfizer and Moderna COVID-19 vaccines. These vaccines contain mRNA, a genetic cousin of DNA, that prompts cells to make the coronavirus "spike protein." The vaccines don't alter cells' DNA, and after making the spike, cells break down most of the mRNA. Other COVID-19 shots include the viral vector vaccines made by AstraZeneca and Johnson & Johnson, which deliver DNA into cells to make them build spike proteins. The cells that make spike proteins, using instructions from either mRNA or viral vector vaccines, serve as target practice for the immune system, so they don't stick around long. That's very, very different from gene therapy, which aims to change cells' function for the long-term.

Let's take a dive into what gene therapy actually is, addressing some common questions along the way.

DNA is a molecule that stores genetic information, and genes are pieces of genetic information that cells use to make a particular product, such as a protein. DNA is located inside the nucleus of a cell, where it's packaged into chromosomes, and also inside mitochondria, the "power plant" organelles located outside the nucleus.

Although there are mitochondrial diseases that could someday be cured with gene therapy, currently, the term gene therapy refers to treatments that target nuclear genes the genes on the 23 pairs of chromosomes inside the nucleus.

Classically, gene therapy has referred to the process of either "knocking out" a dysfunctional gene or adding a copy of a working gene to the nucleus in order to improve cell function. Gene therapy is currently directed at diseases stemming from a problem with just one gene, or at most a few genes, rather than those that involve many genes.

However, the field of gene therapy is now expanding to include strategies that don't all fall into the classic categories of knocking out bad genes or adding good genes. For example, researchers at Sangamo Therapeutics are developing genetic techniques for treating Parkinson, Alzheimer and Huntington diseases that work by ramping up or suppressing the activity of specific genes.

While the treatments may add genes to body cells, knock out genes or act in some way to change the function of genes, each gene therapy is directed to the cells of particular body tissues. Thus, when scientists and doctors talk about what gene therapy does to DNA, they are not talking about all of the DNA in the body, but only some of it.

Gene therapy can be either ex vivo or in vivo.

Ex vivo gene therapy means that cells are removed from the body, treated and then returned to the body. This is the approach used to treat genetic diseases of blood cells, because bone marrow can be harvested from the patient, stem cells from that bone marrow can be treated with gene therapy for instance, to supply a gene that is missing or not working correctly and the transformed cells can be infused back into the patient.

In vivo gene therapy means that the gene therapy itself is injected or infused into the person. This can be through injection directly to the anatomic site where the gene therapy is needed (a common example being the retina of the eye), or it can mean injection or infusion of a genetic payload that must travel to the body tissues where it is needed.

In both ex vivo and in vivo gene therapy, the genetic payload is packaged within a container, called a vector, before being delivered into cells or the body. One such vector is adeno-associated virus (AAV). This is a group of viruses that exist in nature but have had their regular genes removed and replaced with a genetic payload, turning them into gene therapy vectors.

AAV has been used to deliver gene therapy for many years, because it has a good safety record. It is much less likely to cause a dangerous immune response than other viruses that were used as vectors several decades ago, when gene therapy was just getting started. Additionally, packaging genetic payloads within AAV carriers allows for injected or infused gene therapy to travel to particular body tissues where it is needed. This is because there are many types of AAV, and certain types are attracted to certain tissues or organs. So, if a genetic payload needs to reach liver cells, for example, it can be packaged into a type of AAV that likes to go to the liver.

In the early days of gene therapy, which began in 1989, researchers used retroviruses as vectors. These viruses delivered a genetic payload directly into the nuclear chromosomes of the patient. However, there was concern that such integration of new DNA into chromosomes might cause changes leading to cancer (opens in new tab), so the strategy was initially abandoned. (More recently, scientist have successfully used retroviruses in experimental gene therapies without causing cancer; for example, a retrovirus-based therapy was used to treat infants with "bubble boy disease.")

After moving away from retroviruses, researchers turned to adenoviruses, which offered the advantage of delivering the genetic payload as an episome a piece of DNA that functions as a gene inside the nucleus but remains a separate entity from the chromosomes. The risk for cancer was extremely low with this innovation, but adenovirus vectors turned out to stimulate the immune system in very powerful ways. In 1999, an immune reaction from adenovirus-carrying gene therapy led to the death of 18-year-old Jesse Gelsinger, (opens in new tab) who'd volunteered for a clinical trial.

Gelsinger's death shocked the gene therapy community, stalling the field for several years, but the current gene therapies that have emerged over the years based on AAV are not dangerous. However, they tend to be expensive and the success rate varies, so they typically are used as a last resort for a growing number of genetic diseases.

Gene therapy can treat certain blood diseases, such as hemophilia A, hemophilia B, sickle cell disease, and as of 2022, beta thalassemia (opens in new tab). What these diseases have in common is that the problem comes down to just one gene. This made beta thalassemia and sickle cell disease low-hanging fruits for ex vivo gene therapies that involve removing and modifying bone marrow stem cells, whereas hemophilia A and hemophilia B are treated with in vivo gene therapies that target liver cells. That said, other treatments exist for these blood diseases, so gene therapy is more of a last resort.

Numerous enzyme deficiency disorders also come down to one bad gene that needs to be replaced. Cerebral adrenoleukodystrophy, which causes fatty acids to accumulate in the brain, is one such disorder that can be treated with gene therapy, according to Boston Children's Hospital (opens in new tab). CAR T-cell therapy, which is approved for certain cancers, involves removing and modifying a patient's immune cells and is known as a "cell-based gene therapy." (opens in new tab)

Gene therapy has also been useful in treating hereditary retinal diseases (opens in new tab), for which other treatments have not been useful.

Another group of targets for gene therapy are diseases of the nervous system.

"We are at a remarkable time in the neurosciences, where treatments for genetic forms of neurological disorders are being developed," Dr. Merit Cudkowicz (opens in new tab), the chief of neurologyat Massachusetts General Hospital and a professor at Harvard Medical School, told Live Science.

For example, gene therapies are being developed to treat a pair of genetic diseases called Tay-Sachs disease and Sandhoff disease. Both conditions result from organelles called lysosomes filling up with fat-like molecules called gangliosides. The effects of these diseases (opens in new tab) include delay in reaching developmental milestones, loss of previously acquired skills, stiffness, blindness, weakness and lack of coordination with eventual paralysis. Children born with Tay-Sachs disease and Sandhoff disease generally dont make it past 2 to 5 years of age.

"There has been no routine antenatal or neonatal test for Tay-Sachs and Sandhoff, because there has been no available treatment whatsoever," said Dr. Jagdeep Walia (opens in new tab), a clinical geneticist and head of the Division of Medical Genetics within the Department of Pediatrics and the Kingston Health Sciences Centre and Queen's University in Ontario, Canada. Walia is developing a gene therapy aimed at replacing the gene for Hex A, the enzyme that is deficient in these children. So far, the treatment has shown good efficacy and safety in animal models, but it still needs to be tested in human patients.

The future looks hopeful when it comes to gene therapy overall, on account of new technological developments, including CRISPR gene editing. This is an extremely powerful technique for cutting out parts of DNA molecules and even pasting new parts in analogous to what you do with text in word processing applications. CRISPR is not the first method that scientists have used to edit DNA, but it is far more versatile that other techniques. It is not yet quite ready for in vivo chromosomal manipulation, but it is advancing exponentially.

Perhaps even closer to the horizon is the prospect of delivering larger genetic payloads into cells. One big drawback of the AAV vector is that each virus particle can carry just a small amount of DNA, but recent research has revealed that a different type of virus, called cytomegalovirus, can be adapted to carry gene therapies (opens in new tab) with a much bigger payload than AAV. Not only might this some day expand gene therapy to more diseases requiring larger genes than AAV can carry, but it also could enable more than one gene to be delivered in a single therapy.

See the original post here:
Gene therapy: Everything you need to know about the DNA ... - Livescience.com

Biologics Outsourcing Market : Latest Research Reveals Key Trends for Business Growth| Lonza Group AG, Wuxi Bi – openPR

Biologics Outsourcing Market

Request Sample Copy @ https://www.themarketinsights.com/request-sample/265110

Market Segmentation

The global biologics outsourcing market has been analyzed on the basis of product type, source, application, end-use, and region. Based on the product type, the market is segmented into antibodies, recombinant proteins, vaccines, and others. Among these, antibodies segment is estimated to hold a prominent share in the market. Based on source, the market is segmented into human, microbial, and others. The microbial segment is projected to exhibit a considerable growth during the forecast period.Based on application, the market is segmented into stem cell research, vaccine and therapeutics development, blood & blood-related products development, cellular and gene therapy products development, and others. Stem cell research segment is estimated to hold a prominent share in the market. Based on end-user, the market covers the analysis of therapeutics & diagnostics, and research. Geographically, the market is analyzed into North America, Western Europe, Eastern Europe, Asia Pacific, Latin America, and Middle East & Africa.

Check for Discount @ https://www.themarketinsights.com/check-discount/265110

Market Structure and Competition Landscape

The global biologics outsourcing market is characterized by the presence of significant number of players. Some of the prominent players operating in the market include Lonza Group AG, Wuxi Biologics (Cayman) Inc., Boehringer Ingelheim International GmbH, Samsung Biologics Co. Ltd., Thermo Fisher Scientific Inc., Wuxi Biologics (Cayman) Inc., Genescript Biotech Corp., and others. Growing focus on biologics and increasing R&D spending on biologics drugs by these industry players are expected to drive the market. Some of the key developments in the global biologics outsourcing market include:In January 2022, Samsung Biologics agreed to pay US$ 2.3 billion for Biogen s 50% stake in Samsung Bioepis, a joint venture between the two companies. This is aimed to improve Samsung Bioepis biosimilar development capabilities and future performance in new drug development.In March 2021, WuXi acquired a single-use biologics production plant in Hangzhou, China, from Pfizer Inc.

Report Customization available as per requirements @ https://www.themarketinsights.com/request-customization/265110

Table of Content

Chapter One: Market Introduction1.1. Scope of Study1.2. Problem Statement1.3. Market SegmentationChapter Two: Assumptions and AcronymsChapter Three: Executive Summary3.1. Global Market in20223.2. Analyst Insights & Recommendations3.3. Growth Opportunities and Key Strategies3.4. Supply-side and Demand-side TrendsChapter Four: Research MethodologyChapter Five: Analysis of COVID-19 Impact and Road AheadChapter Six: Market Indicators and Background6.1. Macro-Economic Factors6.2. Forecasting FactorsRobust assessment of various factors including industrial performance, industry players expenditures, and economic conditions among others6.3. Supply Chain & Value Chain Analysis6.4. Industry SWOT Analysis6.5. PESTLE Analysis6.6. Porter s Five Forces AnalysisChapter Seven: Rules & RegulationsChapter Eight: Global and Regional Market Dynamics8.1. Drivers8.2. Restraints8.3. Trends8.4. OpportunitiesChapter Nine: Global Biologics Outsourcing Market: Key Investment Analysis9.1. By Leading Biologics Companies9.2. Technological Assessment9.3. By Region9.4. M&A ActivitiesRobust assessment of major investments made by various industry players along with key technological assessment, and key end-use sectorChapter Ten: Global Biologics Outsourcing Market: Service Cost Analysis10.1. By Service Type10.1.1. Antibody Production Service10.1.2. Custom Monoclonal Antibody Production Service10.1.3. Custom Polyclonal Antibody Production Service10.1.4. Protein Production Service10.1.5. Gene Editing ServiceChapter Eleven: Global Biologics Outsourcing Market: Biological Development Phase Analysis11.1. Discovery11.2. Pre-Clinical11.3. Clinical11.4. CommercializationChapter Twelve: Parent Market Overview12.1. Global Life Sciences Market12.2. Global Healthcare MarketChapter Thirteen: Segmental Analysis13.1. Global Biologics Outsourcing Market by Product Type13.1.1. Segment Overview13.1.1.1. Antibodies13.1.1.1.1. Monoclonal Antibody13.1.1.1.2. Antibody Drug Conjugates13.1.1.1.3. Others (Polyclonal Antibodies etc. )13.1.1.2. Recombinant proteins13.1.1.3. Vaccines13.1.1.4. Others (Fusion Proteins, etc. )13.2. Global Biologics Outsourcing Market by Source13.2.1. Segment Overview13.2.1.1. Human13.2.1.2. Microbial13.2.1.3. Others (Transgenic Animals such as Avian, Insects, etc. )13.3. Global Biologics Outsourcing Market by Application13.3.1. Segment Overview13.3.1.1. Stem Cell Research13.3.1.2. Vaccine and Therapeutics Development13.3.1.3. Blood & Blood-Related Products Development13.3.1.4. Cellular and Gene Therapy Products Development13.3.1.5. Others (Tissue & Tissue Related Products Development)13.4. Global Biologics Outsourcing Market by End Use13.4.1. Segment Overview13.4.1.1. Therapeutics and Diagnostics13.4.1.2. Research13.5. Global Biologics Outsourcing Market by Region13.5.1. North America13.5.2. Latin America13.5.3. Western Europe13.5.4. Eastern Europe13.5.5. Asia Pacific13.5.6. Middle East & AfricaChapter Fourteen: Regional Analysis14.1. North America Biologics Outsourcing Market Analysis and Forecast2019-202814.1.1. Market Overview14.1.2. North America Biologics Outsourcing Market by Product Type14.1.3. North America Biologics Outsourcing Market by Source14.1.4. North America Biologics Outsourcing Market by Application14.1.5. North America Biologics Outsourcing Market by End Use14.1.6. North America Biologics Outsourcing Market by Country14.1.6.1. US14.1.6.2. Canada14.2. Latin America Biologics Outsourcing Market Analysis and Forecast2019-202814.2.1. Market Overview14.2.2. Latin America Biologics Outsourcing Market by Product Type14.2.3. Latin America Biologics Outsourcing Market by Source14.2.4. Latin America Biologics Outsourcing Market by Application14.2.5. Latin America Biologics Outsourcing Market by End Use14.2.6. Latin America Biologics Outsourcing Market by Country14.2.6.1. Brazil14.2.6.2. Mexico14.2.6.3. Rest of Latin America14.3. Western Europe Biologics Outsourcing Market Analysis and Forecast2019-202814.3.1. Market Overview14.3.2. Western Europe Biologics Outsourcing Market by Product Type14.3.3. Western Europe Biologics Outsourcing Market by Source14.3.4. Western Europe Biologics Outsourcing Market by Application14.3.5. Western Europe Biologics Outsourcing Market by End Use14.3.6. Western Europe Biologics Outsourcing Market by Country14.3.6.1. Germany14.3.6.2. UK14.3.6.3. France14.3.6.4. Spain14.3.6.5. Italy14.3.6.6. Benelux14.3.6.7. Nordic14.3.6.8. Rest of Western Europe14.4. Eastern Europe Biologics Outsourcing Market Analysis and Forecast2019-202814.4.1. Market Overview14.4.2. Eastern Europe Biologics Outsourcing Market by Product Type14.4.3. Eastern Europe Biologics Outsourcing Market by Source14.4.4. Eastern Europe Biologics Outsourcing Market by Application14.4.5. Eastern Europe Biologics Outsourcing Market by End Use14.4.6. Eastern Europe Biologics Outsourcing Market by Country14.4.6.1. Russia14.4.6.2. Poland14.4.6.3. Rest of Eastern Europe14.5. Asia Pacific Biologics Outsourcing Market Analysis and Forecast2019-202814.5.1. Market Overview14.5.2. Asia Pacific Biologics Outsourcing Market by Product Type14.5.3. Asia Pacific Biologics Outsourcing Market by Source14.5.4. Asia Pacific Biologics Outsourcing Market by Application14.5.5. Asia Pacific Biologics Outsourcing Market by End Use14.5.6. Asia Pacific Biologics Outsourcing Market by Country14.5.6.1. China14.5.6.2. Japan14.5.6.3. India14.5.6.4. South Korea14.5.6.5. Australia14.5.6.6. ASEAN14.5.6.7. Rest of Asia-Pacific14.6. Middle East & Africa Biologics Outsourcing Market Analysis and Forecast2019-202814.6.1. Market Overview14.6.2. Middle East & Africa Biologics Outsourcing Market by Product Type14.6.3. Middle East & Africa Biologics Outsourcing Market by Source14.6.4. Middle East & Africa Biologics Outsourcing Market by Application14.6.5. Middle East & Africa Biologics Outsourcing Market by End Use14.6.6. Middle East & Africa Biologics Outsourcing Market by Country14.6.6.1. GCC14.6.6.2. South Africa14.6.6.3. Turkey14.6.6.4. Rest of the Middle East & AfricaChapter Fifteen: Competitive Landscape15.1. Competition Dashboard15.1.1. Global and Regional Market Share Analysis15.1.2. Market Structure15.2. Competitive Benchmarking15.3. Key Strategy Analysis15.4. Company Profiles15.4.1. Lonza Group AG15.4.1.1. Company Overview15.4.1.2. Product/Service Offerings15.4.1.3. Key Financials15.4.1.4. Recent Developments15.4.2. Wuxi Biologics (Cayman) Inc.15.4.2.1. Company Overview15.4.2.2. Product/Service Offerings15.4.2.3. Financials15.4.2.4. Recent Developments15.4.3. Boehringer Ingelheim International GmbH15.4.3.1. Company Overview15.4.3.2. Product/Service Offerings15.4.3.3. Financials15.4.3.4. Recent Developments15.4.4. Abzena Ltd.15.4.4.1. Company Overview15.4.4.2. Product/Service Offerings15.4.4.3. Financials15.4.4.4. Recent Developments15.4.5. GL Biochem Corp.15.4.5.1. Company Overview15.4.5.2. Product/Service Offerings15.4.5.3. Financials15.4.5.4. Recent Developments15.4.6. Catalent, Inc.15.4.6.1. Company Overview15.4.6.2. Product/Service Offerings15.4.6.3. Financials15.4.6.4. Recent Developments15.4.7. Samsung Biologics Co. Ltd.15.4.7.1. Company Overview15.4.7.2. Product/Service Offerings15.4.7.3. Financials15.4.7.4. Recent Developments15.4.8. ThermoFisher Scientific Inc.15.4.8.1. Company Overview15.4.8.2. Product/Service Offerings15.4.8.3. Financials15.4.8.4. Recent Developments15.4.9. Syngene International Ltd.15.4.9.1. Company Overview15.4.9.2. Product/Service Offerings15.4.9.3. Financials15.4.9.4. Recent Developments15.4.10. Rentschler Biopharma SE15.4.10.1. Company Overview15.4.10.2. Product/Service Offerings15.4.10.3. Financials15.4.10.4. Recent Developments15.4.11. Abbvie Inc.15.4.11.1. Company Overview15.4.11.2. Product/Service Offerings15.4.11.3. Financials15.4.11.4. Recent Developments15.4.12. Genscript Biotech Corp.15.4.12.1. Company Overview15.4.12.2. Product/Service Offerings15.4.12.3. Financials15.4.12.4. Recent Developments*List of companies is not exhaustiveChapter Sixteen: Disclaimer

Direct ContactJessica Joyal+1(213)338-8279 | +1(877)376-9989sales@themarketinsights.com

About us.Delivering foresights along with statistical analysis of the operational business industry impacts has been our foremost priority. With the constant developments in the research & development industry, we have always challenged the conventional research methodologies and discovered new research tactics to evolve the growing B2B requirements.

This release was published on openPR.

Read the original post:
Biologics Outsourcing Market : Latest Research Reveals Key Trends for Business Growth| Lonza Group AG, Wuxi Bi - openPR

Down syndrome research : 5 advancements over the year – Labiotech.eu

It was in 1959 when an extra chromosome on the 21st pair in the human cell was discovered by French geneticist Jerome Jean Louis Marie Lejeune. This was followed by research in the discipline of cytogenetics the study of chromosomes. This chromosomal aberration which affects around one in 1000 live births worldwide, is called trisomy 21 or Down syndrome named after the British physician who characterized the condition.

Following the discovery, the first mouse model with Down syndrome was created in 1974 which brought about guidelines for studying other chromosomal abnormalities.

Soon enough, prenatal diagnostic measures like amniocentesis were introduced to detect a fetus with Down syndrome.

Over the years, therapies have been focused on individual physical and intellectual needs, and to battle comorbidities like heart defects and hypothyroidism. Early intervention programs are offered to young children with Down syndrome where they engage with professionals who aid in providing speech and physical therapy, among other assistance.

Although amino acid supplements have been prescribed to people with cognitive disorders as a result of the condition to influence brain activity, recent clinical trials demonstrated adverse side effects. As studies have involved only a few participants, drugs to treat symptoms of dementia in Down syndrome have not proven to be efficacious yet.

However, news drug trials are attempting to fight symptoms, and assistive devices like special pencils to make writing easier, touch screen gadgets and large-letter keyboards have been developed to enhance learning in children.

As we observe World Down Syndrome Day on March 21, here are some of the latest advancements in Down syndrome research.

Although the triplication of chromosome 21 (T21) is an established fact, very little has been known about its effect on transcription in the nucleus of cells.

However, a study conducted by researchers at the Massachusetts Institute of Technology (MIT) in the U.S., has shed light on the interplay between T21 and transcriptome, which is the sequence of messenger RNA molecules.

It was found that, unlike human induced pluripotent stem cells (iPSCs), iPSC-derived neural progenitor cells (NPCs) exhibit chromosomal introversion characterized by more genetic interaction within each chromosome rather than among them and changes in chromatin accessibility a factor that influences the regulation of gene transcription. The research findings have indicated a link between Down syndrome and senescence (associated with aging), affecting neurodevelopment.

The treatment of the T21-harboring NPCs with senolytic drugs, which selectively clear senescent cells, alleviated some of the biological dysfunctions associated with Down syndrome, according to Fady Riad, CEO of consulting firm Centurion Life Sciences.

Riad expressed that senolytics like dasatinib and quercetin might be potential therapeutic options for patients since they may alleviate cellular and molecular dysfunction in NPCs.

The Spanish Hospital del Mar Medical Research Institute is conducting a phase 1b clinical trial to test the safety and efficacy of a new treatment to improve cognitive function in people with Down syndrome.

As studies have shown that people with Down syndrome have a hyperactivated CB1 cannabinoid receptor, the drug candidate is based on the modulation of the receptor with specific inhibitors which has proven to be effective on animal models. The French biotech Aelis Farma developed AF0217, a molecule that counteracts the hyperactivity of CB1 cannabinoid in the brain.

With funding from the European Union (EU), the team at the Spanish Hospital del Mar Medical Research had previously conducted a trial phase for AF0217, which was approved by the Spanish Agency for Medicines and Health Products (AEMPS), after having demonstrated that the molecule is well-tolerated.

Lead researcher Rafael de la Torre commented that this was of particular importance for the acceptance of treatment by the families of people with Down syndrome.

Phase 1b trials have recruited 45 patients with Down syndrome aged between 18 and 35.

According to Riad: This development is part of a wave of growing interest in the therapeutic potential of modulating the endocannabinoid system.

People with Down syndrome are often at the risk of being diagnosed with Alzheimers disease (AD), with a 90% lifetime incidence of AD. This is because amyloid plaques protein clumps that collect between neurons and disrupt cell function, an indicator of Alzheimers are often found in individuals in their 40s with Down syndrome, because of excessive amyloid plaque formation due to the extra copy of the APP gene encoding the amyloid precursor protein found on chromosome 21.

To battle Alzheimers, Swiss biotech AC Immune developed a vaccine candidate that inhibits plaque formation in the brain. The ACI-24.060 vaccine is designed to elicit an antibody response by the patients own immune system against pathological species of amyloid beta, according to Andrea Pfeifer, CEO of AC Immune. The mechanism is similar to that of Leqembi, an FDA-approved drug for the treatment of AD.

The vaccine, which is being studied in the ongoing phase 1/2 ABATE trial in Alzheimers disease, will be administered to the first individual from a Down syndrome cohort soon. This followshavingsuccessfully completed an early stage clinical trial which demonstrated its safety and immunogenicity in people with Down syndrome.

Pfeifer said: The lack of treatment options to address amyloid pathology in Down syndrome is unacceptable, as people living with Down syndrome represent the largest population with early onset Alzheimers disease. The individuals themselves together with their families are searching for therapies to help improve their quality of life and, as our first clinical study has shown, are willing to participate actively in the development of a solution.

An effective vaccine could potentially offer a means of prevention or reduction of disease severity and have a major impact on the lives of people living with Down syndrome, said Pfeiffer, who added that after an initial priming phase in the first year, the vaccine could be dosed annually or bi-annually as a booster to ensure that adequate antibody levels are maintained.

Pfeiffer expressed that the research will further raise the profile of the unmet medical need for individuals with Down syndrome and managing Alzheimers disease from which they almost invariably suffer.

Researchers at the University of Arizona have developed a drug that could slow the progression of AD in people with Down syndrome.

The drug, which decreases levels of DYRK1A an enzyme kinase which is excessively produced due to the overexpression of the DYRK1A gene in patients with AD has exhibited its effectiveness at suppressing AD symptoms, confirming their therapeutic potential in animal models.

Previously, DYRK1A inhibitor drugs have proven efficacy in mice models with AD, while the enzyme has been studied in Drosophila (fruit fly) with genetically engineered AD phenotypes, which showed that the overexpression of the DYRK1A gene led to photoreceptor neuron degeneration, decreased locomotion, sleep and memory loss.

According to Riad, the results are encouraging as the study focuses on an unmet medical need and paves the way for human clinical trials, however, there is the challenge of proving the drugs efficacy in human clinical trials, despite its success in preclinical studies.

A new research has confirmed a correlation between the secretion of gonadotropin-releasing hormone (GnRH), which is responsible for regulating the sex hormones and is produced in the neurons in the brain, and cognitive processes in Down syndrome. Moreover, the study showed that GnRH therapies could be given to patients with Down syndrome to boost brain connectivity.

The research conducted by a team at University of Lille in France, was initially studied in mice models with Down syndrome. It was observed that the mice had deficiencies of GnRH and an imbalance in a network of microRNAs, particularly around the trisomic regions; which affects neuronal activity, olfaction, and cognition.

The mice were then treated with cell therapy and chemogenetic interventions to produce GnRH, which showed promising results where they developed cognitive abilities similar to those of healthy mice.

This research led the team to partner with researchers at University of Lausanne in Switzerland, where trials were conducted on patients with Down syndrome. Patients were given GnRH replacement therapy drug Lutrelef every 2 hours for 6 months a therapy which is used to treat GnRH-deficient conditions like Kallmann syndrome, a condition that delays or prevents puberty. The success of the results was demonstrated by improved cognitive performance in patients.

More large-scale trials are needed but this is encouraging because GnRH replacement therapies have long been studied in humans and their safety profile is very well understood which means that an eventual path to regulatory approval will be rather straightforward, said Riad.

New technologies related to Down Syndrome research

See the rest here:
Down syndrome research : 5 advancements over the year - Labiotech.eu

COPHy 2023: Durability associated with multi-target therapies is … – Ophthalmology Times Europe

Antonio Campos, MD, PhD, made a presentation at the Congress on Controversies in Ophthalmology. He discusses his position on a discussion titled Durability Associated with Multi-target Therapies is Superior to anti-VEGF Mono-target Therapy in AMD with David Hutton, Executive Editor,Ophthalmology Times.

Editors note: This transcript has been edited for clarity

Hello, I'm David Hutton of Ophthalmology Times. The 14th annual Congress on controversies in Ophthalmology is being held this year in Lisbon, Portugal. At the event physicians present the pros and cons on a number of topics. Dr. Antonio Campos defended the negative position on a discussion titled Durability Associated with Multi-target Therapies is Superior to anti-VEGF Mono-target Therapy in AMD. Thanks for joining us today. Tell us about your discussion.

This is related mainly with the new faricimab versus aflibercept. And we know that angiopoietin-2 is not elevated in several cases of AMD, and 42% of the patients in the TENAYA and LUCERNE studies didn't have actually angiopoietin-2 levels elevated. Besides, there's another blocker of angiopoietin-2 that was used in ONYX trial of nesvacumab that didn't prove to be effective. And one should expect that in diabetic retinopathy studies and the recent BALATON and communal studies of retinal vein occlusion, where angiopoietin-2 is really elevated that the dual-action blocking angiopoietin-2 should have better results. But actually, that didn't prove to be right. So we must not forget that faricimab has a higher dosage than aflibercept [inaudible]. Well, the completion of the study was not perfect, and probably dosage and bioavailability will respond for most of the differences. According to my position, regulatory authorities, such as FDA and MA in Europe, also pointed out that it's not proven that there is an effective dual blocking mechanism in those medicines.

*Anat Loewenstein presented the affirmative position on this topic.

More here:
COPHy 2023: Durability associated with multi-target therapies is ... - Ophthalmology Times Europe

Here’s Why Axolotls Are Disappearing – Green Matters

By Eva Hagan

Mar. 24 2023, Published 1:36 p.m. ET

Article continues below advertisement

The carnivorous salamander native to the lakes of Mexico, the axolotl (pronounced AX-oh-lot-ul), is facing extinction primarily due to human development, habitat loss, droughts, wastewater disposal, and climate change, per National Geographic.

Article continues below advertisement

According to Reuters, axolotls once swam all throughout Xochimilco's canals, however, polluted water due to urban sprawl and the increase in non-native species competition has led the population to decrease.

Article continues below advertisement

Although the axolotl is often bred in labs and captivity, they continue to decline in the canals of Mexico City, their only remaining natural habitat.

According to Vox, axolotl habitat destruction started as early as the Spanish invasion during colonization, where the growth and development of Mexico City sent chemicals and sewage into local waterways, changing ecosystems forever. Since then, fertilizers, pollution, chemicals, etc. have only increased, as well as the introduction of non-native species that outcompete native species like axolotls.

Article continues below advertisement

Article continues below advertisement

Axolotls have been popular in the aquarium and pet trade since the 19th century, traveling from Mexico to all over Europe.

The axolotl has been studied for its impressive ability to regrow tissues in the skin, muscles, heart, brain, etc., and its capacity to resist cancerous tissues. Because of its unique abilities, the axolotl was even considered in legends as Xototl, the Aztec god of fire and lightning, disguised as a salamander.

Article continues below advertisement

Axolotls live anywhere from 10 to 15 years and differ from other salamanders and amphibians because they seem to stay young forever, a marvel called neoteny, where they keep their baby traits and physical features their whole life.

However, although they remain cute, they are carnivorous and feed on crustaceans, mollusks, eggs, and fish, per National Geographic.

A research article published in 2016 by the Department of Stem Cell and Regenerative Biology at Harvard University found that axolotls are able to regrow parts of their brain after injury, growing diverse sets of neurons.

Article continues below advertisement

Their ability to do this, along with regrowing entire parts of their body with not so much as a scar, is deemed a superpower in the scientific world. According to an interview between the Boston Museum of Science and Fallon Durant, an axolotl researcher, scientists are studying axolotls to determine what parts of their DNA help them regenerate, and resist things like cancer. If this can be understood and replicated, it could be a game changer for human therapeutics.

Continued here:
Here's Why Axolotls Are Disappearing - Green Matters

19th Annual Bouchet Conference Recognizes Diversity and … – Yale University

The 19th Annual Bouchet Conference on Diversity and Graduate Education, hosted by the Office for Graduate Student Development and Diversity in the Graduate School of Arts and Sciences, will take place on March 31-April 1, 2023. This years theme The Role of the Academy in Preserving a Democracy will delve into the ways in which the academy, and graduate education in particular, prepares future leaders for service tosociety.

Named for Edward Alexander Bouchet, the first African American doctoral recipient in the United States, the Edward Alexander Bouchet Graduate Honor Society recognizes outstanding scholarly achievement and promotes diversity and excellence in doctoral education and the professoriate. The Bouchet Society was inaugurated on Thursday, September 15, 2005, with a simulcast ceremony held at Yale University and Howard University. There will be 122 inductees this year from 19 Bouchet Graduate Honor Society chapterinstitutions.

Yales Graduate School hosts an annual induction ceremony and simultaneous conference featuring panel presentations and poster sessions from members of the honor society on topics ranging from artificial intelligence to Black feminist literature. The conference will feature a keynote address by this years Bouchet Leadership Award Medal recipient David A. Thomas, President of Morehouse College. Yale will induct six new members to its chapter during the ceremony: William D. Shipman II, MD, PhD, dermatology resident and postdoctoral fellow in the Yale Department of Dermatology; Eric Glover, MMUF PhD, assistant professor adjunct at Yale David Geffen School of Drama; Ngozi Akingbesote, PhD candidate in cellular and molecular physiology; Sandy Chang, MD, PhD, professor of laboratory medicine, pathology, and molecular biophysics and biochemistry; Mariam O. Fofana, MD, PhD, postdoctoral associate in the Department of Epidemiology of Microbial Diseases at the Yale School of Public Health and clinical instructor in emergency medicine at the Yale School of Medicine; and Paola Figueroa-Delgado, PhD candidate in the Department of CellBiology.

The conference will also feature an award ceremony honoring this years Bouchet Graduate Honor Society Distinguished Service Award recipient Karen P. DePauw, Vice President and Dean for Graduate Education at VirginiaTech.

Brief bios of this years Yale Bouchet Graduate Honor Society inductees can be foundbelow:

William D. ShipmanDermatology

William D. Shipman III MD, PhD is a Dermatology resident and postdoctoral fellow in the Yale Department of Dermatology. His research and clinical interests focus on skin of color, wound healing, and hidradenitis suppurativa. He is originally from North Carolina and is a proud graduate of Morehouse College in Atlanta, GA, obtaining a Bachelor of Science degree in Biology. From there, he completed an MD-PhD program at the Weill Cornell/Rockefeller/ Sloan-Kettering Tri-Institutional program in NYC, receiving a PhD in Immunology- studying autoimmune skin diseases and specially discovering that immune cells are dysfunctional in lupus skin, working with Dr. Theresa Lu- a Yale Medicine MD/PhD alumna. During graduate school he also worked on projects in skin fibrosis and lymph node fibroblast function in immunity. At Weill Cornell he was involved in creating the Black and Latino Men in Medicine organization, which has since resulted in consultation from other academic centers. He completed a preliminary year in Internal Medicine at Yale-New Haven Hospital and is currently completing his residency in Dermatology with a combined postdoctoral fellowship component. His postdoctoral work will be done with Dr. Henry Hsia- Professor of Plastic Surgery and Founder of Yale Regenerative Wound Healing Center, studying the role of extracellular vesicles in wound healing and hidradenitis suppurativa. In addition to his clinical and research efforts, Dr. Shipman serves as an advocate to promote diversity, equity, and inclusion within his department and within Dermatologynationally.

Eric M. GloverDramaturgy and DramaticCriticism

Eric M. Glover, MMUF PhD, is an assistant professor adjunct at Yale David Geffen School of Drama, where he practices dramaturgy and dramatic criticism. Glover is the author of African-American Perspectives in Musical Theatre (London: Bloomsbury Publishing Plc, 2023), where he reads representative musicals by and about Black peoplefrom Pauline Elizabeth Hopkins to Stewclosely. Glover is also editing Manifestos for BlackTheatre, Then and Now, a special section of TheatreHistory Studies, with Isaiah Matthew Wooden at Swarthmore. A member of the advisory board for the Web site Extended Play: TheaterBeyond the Theater and also a member of the editorial board for the scholarly journal Studies in Musical Theatre. Glover is also serving as a production dramaturg at Yale Repertory Theatre for Christina Anderson's play the ripple, the wave thatcarried me home. Black Theater History in the Making at Yale School of Drama, Black Women Playwrights, Race and the American Musical from Jerome Kern to Jay Kuo, and Topics in Casting comprise courses taught. Glover is also proud to be the first-ever self-identified African-American dramaturgy and dramatic criticism faculty member at the School of Drama in itshistory.

Ngozi AkingbesoteCellular and MolecularPhysiology

Ngozi is a candidate for the Ph.D. in Cellular and Molecular Physiology with a concentration in Cancer Metabolism at Yale University. Her research focuses on uncovering the mechanisms by which exercise improves therapeutic responses to immunotherapy in triple-negative breast cancer preclinical models. Her first author paper revealing, A precision medicine approach to metabolic therapy for breast cancer in mice, is published in Communications Biology. Ngozi was awarded the Yale Presidents Public Service Fellowship in 2021, where she got the opportunity to work with the Sickle Cell Disease Association of America (Michelles House), a Connecticut-based organization that seeks to use prevention strategies to enhance the quality of life and well-being of the community affected by sickle cell disease (SCD). Additionally, Ngozi was awarded one of the Yale Deans Emerging Scholars Research Awards in 2022. Currently, Ngozi serves as the Outreach chair for the Yale BBS Diversity and Inclusion Collective (YBDIC) where she works to leverage resources within Yales network to create STEM education opportunities for minority undergraduate, community school, and post-baccalaureate students. Ngozi also serves as a Public Service Fellow with Yale McDougal Graduate Student Center, where she helps create opportunities for graduate students to interact with the New Haven community through communityservice.

Sandy ChangTelomere Biology and MolecularDiagnostics

Dr. Sandy Chang is a physician-scientist with a research focus on telomere biology and a clinical interest on molecular diagnostics. He has been an important contributor for over two decades in advancing our understanding of how telomeres, repetitive sequences that cap the ends of eukaryotic chromosomes, protect chromosomal ends from being recognized as damaged DNA. The Chang lab has generated many unique mouse models of telomere dysfunction to address innovative questions in both the aging and cancer fields. For example, his lab was the first to generate a mouse model of human Werner Syndrome that recapitulated many of its clinical aging phenotypes. His lab has published their findings in prestigious scientific journals including Nature, Science and Cell. Dr. Chang has been a direct mentor to many PhD students who have gone on to have productive academic research careers. At Yale College, he teaches two First Year Seminars, Topics in Cancer Biology and Perspectives in Biological Research. In both classes, students learn to read and present primary scientific literature and write research proposals that they use to secure summer research funding. As the Associate Dean of STEM Education at Yale College, Dr. Chang is also the director of the Science, Technology and Research (STARS) Programs. STARS supports successful integration of women and underrepresented minorities into Yale STEM classes and laboratories through peer mentorship, professional development workshops and experiential research opportunities. In this capacity, Dr. Chang has increased by over 300% the number of URM and FGLI undergraduates participating in STARSPrograms.

Mariam FofanaEpidemiology of MicrobialDiseases

Mariam O. Fofana is a Postdoctoral Associate in the Department of Epidemiology of Microbial Diseases at the Yale School of Public Health and a Clinical Instructor in Emergency Medicine at the Yale School of Medicine. Her research focuses on the application of quantitative epidemiologic methods such as mathematical modeling to guide the control of infectious disease threats in under-resourced settings and marginalized populations. Her previous work includes estimating the cost-effectiveness of interventions to prevent and treat HIV in South Africa and quantifying the impact of changes in tuberculosis treatment delivery on transmission. Her current work focuses primarily on immune responses, transmission dynamics and socioeconomic impact of SARS-CoV-2 in an urban informal settlement in Brazil. She is determined to make global health more equitable and sustainable through her research as well as education and advocacyefforts.

Paola Figueroa-DelgadoCellBiology

Paola Figueroa-Delgado is a Ph.D. Candidate in the Department of Cell Biology at the Yale School of Medicine. Her research focuses on studying the underlying mechanisms mediating neuronal remodeling in Caenorhabditis elegans. Her thesis work will increase our understanding of fundamental processes that shape the nervous system and will provide insights into how neurodevelopmental disorders may arise. Paola is a recipient of the National Institutes of Health National Research Service Award Predoctoral Fellowship which supports her thesis work and training. In addition, she is the recipient of Yales Annie Le Fellowship for her contributions to science and to the Yale community. Beyond her thesis work, Paola serves as the Director for the Yale Biological and Biomedical Sciences Diversity and Inclusion Collective (YBDIC), an initiative that aims to engage, empower, and advance underrepresented minorities in the biological and biomedical sciences. Through YBDIC, Paola developed and launched programs that provide science education and communication opportunities to community college, undergraduate, and post-baccalaureate students. Among them: mentoring programs (matching over 70 local and national students with current Yale students); a science communication series; and, most notably, a research symposium which hosted 60 local and national students at Yale. In addition, Paola is Student Coordinator for the Yale BioMed Amgen Scholars Program, where she has mentored and supported over 40 undergraduates pursuing a summer research experience at Yale. Her work in service to Yale and her community have awarded her the Yale-Jefferson Award for Public Service and the Vanderbilt Basic Sciences Hispanic and Latin Heritage Graduate LeaderAward.

Read more here:
19th Annual Bouchet Conference Recognizes Diversity and ... - Yale University

50 Celebrity Activists With a History of Protesting Injustice – Good Good Good

Despite calls for actors, athletes, musicians, and other celebrities to eschew activism to focus on entertainment, there is a long-standing precedent for famous people to leverage their platforms to enact change.

From Harry Belafonte and Sidney Poitier establishing themselves as leaders during the civil rights movement to Leonardo DiCaprio and Jane Fonda among many stars pushing for environmental protections and justice, hundreds if not thousands of celebrities in the last century have pushed the needle on a wide variety of causes.

Todays celebrities commonly use their mantles to protest animal cruelty, police brutality, government surveillance, military action, environmental injustice, and civil rights among dozens of other causes.

Our partners at Stacker have compiled a collection of 50 celebrities from the last 75 years with a history of protest. The list includes actors, athletes, and musicians. Several of the contemporary stars made headlines in 2020 for their efforts in support of the Black Lives Matter movement, appearing at numerous protests in the wake of the killings of Breonna Taylor, George Floyd, and many others. Others were instrumental in successful efforts to shut down the Keystone XL pipeline. The Good Good Good team also made some edits and adjustments to the article.

Keep reading to find out what causes some of your favorite celebrities are fighting for.

PS: You might also like: Good Good Goods Guide To Different Types of Activism

Actor Jane Fonda has been known for her activism throughout her decades-spanning career. She was arrested in 1970 for protesting the Vietnam War.

Despite continued action against the conflict, Fonda avoided further arrests until 2019, when she was arrested five times while protesting fossil fuels and calling for environmental action.

Legendary boxing champion Muhammad Ali became an outspoken figure against the Vietnam War, refusing to join the U.S. Army. Declaring himself a conscientious objector, in part due to his religious beliefs, Ali was arrested and stripped of his titles.

Ali became a countercultural figure for civil rights and pacifism, and his conviction for draft evasion was eventually overturned by the Supreme Court.

Avengers star Mark Ruffalo is one of the highest-profile activists against fracking, participating in multiple protests against oil companies.

Ruffalo also produced and starred in a 2019 anti-fracking film called Dark Waters and co-founded The Solutions Project, an organization providing funding for climate justice projects in the U.S. and Puerto Rico.

While fracking has been a central issue for Ruffalo for decades, the actor also protested against former President Donald Trump's policies during his term, and was one of the few celebrities to call for justice for Palestine in 2021.

As a musician, Alicia Keys has added musical flair to her activism. Keys spoke at various demonstrations protesting Trump administration immigration policies, the nomination of Brett Kavanaugh to the Supreme Court, and police brutality, and contributed several protest songs speaking to some of these issues, notably Perfect Way to Die.

As one of the most prolific celebrities in Hollywood, George Clooney has used his star power time and again to bolster his humanitarian efforts.

Clooney had long been vocal about finding a resolution to the War in Darfur, interfacing with world leaders and the United Nations as well as taking part in a number of documentaries spreading awareness about the conflict. In 2012, Clooney was arrested along with his father during a protest at the Sudanese Embassy in Washington D.C.

In 2020, Clooney and his wife Amal donated $500,000 to the Equal Justice Initiative following the murder of George Floyd.

Actor Rosario Dawson is a well-documented activist, primarily demonstrating in support of the Democratic Party. In 2004, Dawson was arrested during the Republican National Convention while protesting against President George W. Bush. She also protested in Washington D.C. in 2016 while attending a rally and spoke out against the role of money in politics.

Dawson founded the non-profit organization Voto Latino, which works to motivate young Hispanic and Latino Americans to register to vote.

Her political activism led her to a fundraiser for Ben Jealous, a 2018 gubernatorial candidate for Maryland, where she met her previous partner, Senator Cory Booker.

Oscar-winning actor Marlon Brando was influential not only for his roles in films like The Godfather and On the Waterfront, but also for his political idealism and activism.

Brando participated in the movement for civil rights in the 1960s and favored a boycott toward South Africa for its apartheid policies.

In support of Indigenous people in the Americas, Brando refused to accept his Best Actor trophy at the 1973 Academy Awards and sent Native American actor Sacheen Littlefeather to speak on his behalf.

Active in a number of social causes, actor Eartha Kitt advocated for and supported underprivileged children in Los Angeles. Kitt also protested against the Vietnam War, and as with many politically active celebrities at the time, she was surveilled by the CIA. Her most public and vocal criticism of the war came during a White House luncheon that President Lyndon Johnson attended.

Former Superman Christopher Reeve had a well-documented history of human rights and environmental activism dating back to at least the mid-70s. He was very involved with Americas Watch, Amnesty International, The Environmental Air Force, Natural Resources Defense Council, and Save the Children.

He flew to Santiago, Chile, in 1987 in support of 77 actors whom the Pinochet regime threatened to execute.

Thrown from a horse and paralyzed in 1995, Christopher Reeve spent the rest of his life and career advocating for stem cell research and the treatment of neurological disorders. He creating the Christopher and Dana Reeve Foundation to fund research and improve the quality of life for patients, testified in support of federal funding for stem cell research before the Senate Appropriations Subcommittee on Labor, Health and Human Services, Education and Related Agencies, and successfully helped get the budget for that National Institute of Health doubled over the course of five years.

The power couple of former Beatle John Lennon and musician and artist Yoko Ono primarily focused on promoting peace with their works of art, with Imagine and Give Peace a Chance being some of the more famous songs from the duo.

The Nixon administration attempted to deport Lennon from the United States over the musician's outspoken leftist politics.

Following Lennons murder in 1980, Ono has continued with her peace activism and art through today; she had a massive retrospective exhibit called Peace is Power in 2019 at the Leipzig Museum of Fine Arts in Germany.

Actor Woody Harrelson has made many of his sociopolitical views known to the public, including his support for marijuana legalization and environmental protection.

At a 1996 protest, Harrelson and several other protesters scaled the Golden Gate Bridge to hang up a sign criticizing Maxxam Inc. CEO Charles Hurwitz.

The outspoken activist and vegan narrated the 2020 documentary Kiss the Ground, which centers on promoting regenerative agriculture as a method for mitigating ecologically damaging farming practices from fossil-fuel use to factory farming.

After coming out at the Human Rights Campaigns Time to Thrive conference in 2014, actor Elliot Page became a public advocate for LGBTQ+ rights. In an anti-Donald Trump protest after the presidents inauguration, a video of Page debating a homophobic preacher went viral online.

After coming out as transgender in December of 2020, Page has become an outspoken advocate and activist for trans issues.

Being one of the most famous actors in film today benefited Leonardo DiCaprios environmental activism. For the bulk of his career, DiCaprio has been active in efforts for preservation and combating climate change.

His activism led to him conferring with national leaders, donating millions of dollars to environmental causes, attending marches, and speaking out about climate change in his acceptance speech for Best Actor at the 88th Academy Awards.

He formed the Leonardo DiCaprio Foundation in 1998 (now part of Earth Alliance), which forms partnerships with organizations, experts, and activists to foster biodiversity and mitigate climate change.

In support of the Black Lives Matter movement, musical artist Janelle Monae wrote and performed a protest song called Hell You Talmbout, which invoked the names of several Black Americans who were victims of police violence and racially motivated crimes. Monae also marched in Black Lives Matter protests.

Actor James Cromwell, who became a vegan while shooting the film Babe, began his activism during the civil rights movement and Vietnam War. He was arrested in 1971 for civil disobedience at the famed May Day anti-war protests in Washington D.C.

His half-century-plus of activism has run the gamut from environmental issues, peace efforts, animal rights, and equality.

He has participated in Black Lives Matter protests back to at least 2017, served as a spokesperson for PETA, was arrested during a protest against a dog laboratory in 2019.

Divergent and The Fault in Our Stars actor Shailene Woodley is an avid activist for environmental issues and is active in a number of progressive organizations. While protesting against the Dakota Access Pipeline, Woodley was arrested and charged with criminal trespassing.

Rapper and actor Yasiin Bey, also known as Mos Def, has been outspoken about police brutality and violence against Black Americans.

He held an impromptu concert outside the MTV Video Music Awards in 2006, performing a protest song called Katrina Clap that criticized the Bush administrations response to the Hurricane Katrina disaster. Despite having a permit, Mos Def was arrested for the performance.

French actor Adle Haenel (Portrait of a Lady on Fire) has been active in France's #MeToo movement. Having had her own experiences with abuse and harassment in the film industry, Haenel in 2020 protested Roman Polanski's win at the Csar Awards by walking out of the ceremony with several others.

The daughter of Honduran immigrants, actor America Ferrera has spent most of her career encouraging and mobilizing Latin Americans to be politically active.

Ferrera spoke several times at Democratic national conventions as well as at the 2017 Womens March.

She has also served as a prominent voice in the Keep Families Together movement against family separations at the U.S.-Mexico border and served as an artist ambassador for the global organization Save the Children.

When winning multiple awards for his lead role in the film Joker, Joaquin Phoenix used the awards stage to promote diversity in the film industry and awareness of animal cruelty.

His 2020 speech at the Oscars specifically condemned the dairy industry for its treatment of cows. Phoenix was arrested in 2020 while protesting the climate crisis along with Jane Fonda and Martin Sheen.

Model Emily Ratajkowski has used her platform to advocate for feminism, sexual expression, and a positive body image.

She has designed dresses with partial proceeds supporting Planned Parenthood, and leveraged her Instagram profile to speak out against an Alabama state law that banned abortion.

Upon the nomination and eventual confirmation of Brett Kavanaugh to the Supreme Court, Ratajkowski and others were arrested at a protest in Washington D.C.

Star of Cheers and The Good Place, Ted Danson has been an outspoken voice for environmental issues, particularly those concerning the worlds oceans.

Danson, in late 2019, participated in one of Fondas many protests demanding action on climate change and arrested alongside her.

Along with being legendary performers on stage and screen, married couple Ossie Davis and Ruby Dee were also both prominent activists in the civil rights movement.

Organizing a number of marches, the two were also friends with Martin Luther King Jr., Jesse Jackson, and Malcolm X, with Davis delivering eulogies for King and Malcolm X.

During a period in which politicians such as Joseph McCarthy were leading a fight against communism in America, several individuals and figures in the film industry were targeted and blacklisted for their suspected political alignments. Classic Hollywood actor Humphrey Bogart organized the Committee for the First Amendment and protested the House Un-American Activities Committee.

The multi-talented Sammy Davis Jr. was also politically active, supporting the election campaigns of John F. Kennedy and Robert Kennedy, although he later became close with Richard Nixon a friendship he eventually regretted.

Regardless, Davis remained active in the civil rights movement, especially after the assassination of Martin Luther King Jr., and criticized Nixon for his shortcomings on civil rights.

Australian actor Cate Blanchett has been outspoken up about the role of women in the film industry. Blanchett is also a longtime ambassador for the Australian Conservation Foundation. She has also advocated for the rights and protection of refugees.

Since his time as a student, Lethal Weapon star Danny Glover has been an activist fighting for civil rights and worker unions.

Politically, Glover has endorsed progressive candidates running for president of the United States.

Glover was arrested in 2010 in Maryland during a protest for better working wages and conditions outside French food corporation Sodexo.

In May of 2021, Glover spoke at a rally against anti-Asian bias in New York City.

Hermione Granger herself, actor Emma Watson, was appointed as a U.N. Women Goodwill Ambassador in 2014.

Watson has used her worldwide fame to speak out about womens issues and human rights and declared her support for transgender people after transphobic comments from Harry Potter author J.K. Rowling.

In 2021, Watson was one of 400 signatories in a letter demanding the UK government include women in decision-making roles at the 2021 UN Climate Change Conference.

Read some of Emma Watsons top book recommendations

Martin Sheen may be famous for his acting, but he has stated that activism is what [he does] to stay alive. A humanitarian and social activist, Sheen has been arrested more than 65 times for protesting. Sheen primarily participates in anti-war, pro-worker, and environmental protests.

Continued here:
50 Celebrity Activists With a History of Protesting Injustice - Good Good Good

2023-03-22 | NDAQ:MRKR | Press Release | Marker Therapeutics Inc. – Stockhouse

2022 CLINICAL AND REGULATORY HIGHLIGHTS

2022 CORPORATE AND FINANCIAL HIGHLIGHTS

HOUSTON, March 22, 2023 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today reported fiscal year 2022 financial results and provided updates for its clinical development programs.

2022 was a critical year for Marker Therapeutics as we advanced the company on several fronts, including key enhancements to our multiTAA clinical development pipeline and strategic initiatives, including with Wilson Wolf, to leverage our differentiated manufacturing capabilities to generate alternative sources of funding for our clinical programs,” said Peter L. Hoang, President and Chief Executive Officer at Marker Therapeutics. We believe these initiatives will unlock multiple value building opportunities for Marker throughout 2023. We continue to advance our MT-401 Phase 2 ARTEMIS clinical trial and are encouraged by recent data involving measurable residual disease (MRD) positive patients, which suggest MT-401 produced with our new T cell manufacturing process could be well suited for this underserved subset of patients with AML. We anticipate reporting a more expansive data readout from the MRD positive group in the second half of 2023."

Mr. Hoang continued: We also made considerable progress with our MT-601 program, securing FDA clearance for INDs in non-Hodgkin lymphoma and pancreatic cancer. We have initiated enrollment for the lymphoma Phase 1 clinical study of MT-601 and expect to report topline data in early 2024 and expect to initiate enrollment for the pancreatic study by the fourth quarter of 2023. We continue to be energized by the manufacturing services agreement with Wilson Wolf and believe we are on track to earn the additional $1 million bonus provided for in the agreement. Additionally, we see the potential to build on the success of this project with additional revenue-generating opportunities whereby we leverage our unique expertise in technical operations to provide the company with non-dilutive capital to fund our clinical programs.”

MT-401 PHASE 2 ARTEMIS (AML)

New manufacturing process for MT-401:

Adjuvant Patients:

Marker continues to see promising data with MRD+ patients:

Measurable residual disease is an important biomarker in hematological malignancies, such as AML, that is used for prognostic, predictive and monitoring assessments. This term refers to a small number of malignant cancer cells remaining in a patient's body after completion of therapy, despite the absence of clinical and radiological evidence of disease. MRD detection relies on highly sensitive laboratory techniques, such as next-generation sequencing, polymerase chain reaction (PCR), or flow cytometry. The assessment is crucial in AML management as it can provide prognostic information and guide therapeutic decisions, such as the need for additional treatment or close surveillance. Importantly, MRD is a transitional phase prior to development of frank relapse and considered a negative prognostic factor. Thus, the achievement of MRD negativity, defined as the absence of detectable malignant cells, is a favorable prognostic factor and an important treatment goal in AML.

The standard first-line treatment for the last decade had been combination chemotherapy using cytarabine and an anthracycline. However, approximately half of the patients eventually relapse. Eligible patients subsequently proceed to hematopoietic stem cell transplantation (HSCT), but disease relapse after transplant is frequent and remains a major cause of death. To date, there is no approved therapy for post-transplant MRD+ patients, highlighting the need for novel therapies. Therefore, the positive clinical responses observed in MRD+ patients treated with MT-401 may provide a more effective approach to treatment.

Our ARTEMIS trial showed promising clinical responses in post-transplant MRD positive patients highlighting the potential benefit of our multiTAA-specific T cell therapy in patients where no treatments have been approved,” said Dr. Juan F. Vera, Chief Scientific Officer and Chief Operating Officer of Marker Therapeutics. We will continue to track the patients’ disease status and look forward to investigating MT-401 in a larger patient population.”

Dr. Vera continued: Our improved T cell manufacturing process used for multiTAA-specific T cells enables a 9-day ex vivo T cell production, providing a fast turnaround for patient treatment to reach MRD positive patients before relapse.”

Frank Relapse Patients:

MT-601 (Lymphoma)

MT-601 (Pancreatic):

FISCAL YEAR 2022 FINANCIAL RESULTS

Cash Position and Guidance: At December 31, 2022, Marker had cash and cash equivalents of $11.8 million. The Company believes that its existing cash, cash equivalents and restricted cash will fund its operating expenses and capital expenditure requirements into the third quarter of 2023.

R&D Expenses: Research and development expenses were $26.1 million for the year ended December 31, 2022, compared to $27.8 million for the year ended December 31, 2021.

G&A Expenses: General and administrative expenses were $12.8 million for the year ended December 31, 2022, compared to $12.9 million for the year ended December 31, 2021.

Net Loss: Marker reported a net loss of $29.9 million for the year ended December 31, 2022, compared to a net loss of $41.9 million for the year ended December 31, 2021.

About Marker's Phase 2 ARTEMIS Trial

The multicenter Phase 2 AML study is evaluating the clinical efficacy of MT-401 in patients with AML following an allogeneic stem-cell transplant in both the adjuvant and active disease setting. In the adjuvant setting, approximately 150 patients will be randomized 1:1 to either MT-401 at 90 days post-transplant versus standard-of-care observation, while approximately 40 patients with active disease will receive MT-401 as part of the single-arm group.

The primary objectives of the trial are to evaluate relapse-free survival in the adjuvant group and determine the complete remission rate and duration of complete remission in active disease patients. Additional objectives include, for the adjuvant group, overall survival and graft-versus-host disease relapse-free survival while additional objectives for the active disease group include overall response rate, duration of response, progression-free survival, and overall survival.

About Marker Therapeutics, Inc. Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Marker’s cell therapy technology is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor associated antigens (i.e. tumor targets) and kill tumor cells expressing those targets. This population of T cells is designed to attack multiple tumor targets following infusion into patients and to activate the patient’s immune system to produce broad spectrum anti-tumor activity. Because Marker does not genetically engineer its T cell therapies, we believe that our product candidates will be easier and less expensive to manufacture, with reduced toxicities, compared to current engineered CAR-T and TCR-based approaches, and may provide patients with meaningful clinical benefit. As a result, Marker believes its portfolio of T cell therapies has a compelling product profile, as compared to current gene-modified CAR-T and TCR-based therapies.

To receive future press releases via email, please visit: https://www.markertherapeutics.com/email-alerts.

Forward-Looking Statements

This release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Statements in this news release concerning the Company’s expectations, plans, business outlook or future performance, and any other statements concerning assumptions made or expectations as to any future events, conditions, performance or other matters, are forward-looking statements.” Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: our research, development and regulatory activities and expectations relating to our non-engineered multi-tumor antigen specific T cell therapies; the effectiveness of these programs or the possible range of application and potential curative effects and safety in the treatment of diseases; the timing, conduct and success of our clinical trials, including the Phase 2 trial of MT-401 and our planned trials of MT-401-OTS and MT-601; our ability to use our manufacturing facilities to support clinical and commercial demand; the success of our new manufacturing process and our collaboration with Wilson Wolf Manufacturing Corporation; and our future operating expenses and capital expenditure requirements. Forward-looking statements are by their nature subject to risks, uncertainties and other factors which could cause actual results to differ materially from those stated in such statements. Such risks, uncertainties and factors include, but are not limited to the risks set forth in the Company’s most recent Form 10-K, 10-Q and other SEC filings which are available through EDGAR at http://WWW.SEC.GOV. Such risks and uncertainties may be amplified by the COVID-19 pandemic and its impact on our business and the global economy. The Company assumes no obligation to update our forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.

Contacts

Investors

Tiberend Strategic Advisors, Inc. Daniel Kontoh-Boateng (862) 213-1398 dboateng@tiberend.com

Media

Tiberend Strategic Advisors, Inc. Jason Rando/Casey McDonald (917)-930-6346/ (646) 577-8520 jrando@tiberend.com/cmcdonald@tiberend.com

See original here:
2023-03-22 | NDAQ:MRKR | Press Release | Marker Therapeutics Inc. - Stockhouse

Tilray Brands Stockholders Approve Charter Amendment to Enhance Corporate Governance and Support Strategic Growth Plan

NEW YORK and LEAMINGTON, Ontario, March 16, 2023 (GLOBE NEWSWIRE) -- Tilray Brands, Inc. (“Tilray Brands” or the “Company”) (NASDAQ | TSX: TLRY), a leading global cannabis-lifestyle and consumer packaged goods company, announced today that Tilray Brands’ stockholders formally approved an amendment to the Company’s Certificate of Incorporation (the “Charter Amendment”). The Charter Amendment will, at the effective time of filing, cancel the Company’s authorized but unissued Class 1 Common Stock and re-allocate such authorized shares to Class 2 Common Stock. At the effective time of filing the Charter Amendment, the Company’s “Class 2 Common Stock” will be reclassified and designated as “Common Stock”. The Charter Amendment is described in more detail in the Company’s Proxy Statement dated September 22, 2022, as supplemented on February 21, 2023.

Excerpt from:
Tilray Brands Stockholders Approve Charter Amendment to Enhance Corporate Governance and Support Strategic Growth Plan